In vitro analysis of combinatory effects of antifungals against highly resistant fungal pathogens

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00007593

Enrollment

Registered

2014-12-05

Start date

2015-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mucormycosis fusariosis B48.7

Interventions

Group 1: Fungal isolates obtained from patients with proven infection by Fusarium spp. or mucormycetes will be identified using molecular methods and subsequently susceptibility tested.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Proven/probable infection according to EORTC/MSG criteria by Fusarium spp. or mucormycetes

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Minimal inhibitory concentrations (MICs) of antifungals tested according to CLSI microdilution method (in vitro)	—

Secondary

Measure	Time frame
Synergy effects of antifungal combinations in vitro	—

Countries

Germany

Contacts

Public ContactAxel Hamprecht

Institut für medizinische Mikrobiologie, Immunologie und HygieneUniversitätsklinikum Köln

axel.hamprecht@uk-koeln.de0221-478 32017

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026